Kelowna’s Lexaria Bioscience has added an American venture capital company founder to its stable of mentors.
Lexaria has appointed Gregg Smith, who is the founder of Evolution VC Partners in New York, as a senior advisor for the company. Evolution VC is a “culture tech” venture investment firm with more than 90 portfolio companies.
“I am passionate about creating a smokeless future and recognize that the consumption methods of nicotine and cannabis will change,” Smith said in a press release. “Lexaria’s technology, DehydraTECH, will completely disrupt and improve the consumption and delivery of oral nicotine, CBD and cannabis.
“Lexaria’s recognition of the recent FDA recognition of certain oral delivery forms of nicotine as ‘less harmful’ to human health than combustible smoking will be a driving force of changing consumer preferences. I expect Lexaria’s technology to play a significant role in that future, and I am pleased to advise the management team at Lexaria in defining our leadership strategies.”
Smith spent 20 years on Wall Street as an investment banker focused on executing private equity placements with a strong focus on life sciences.
Lexaria markets drug delivery platforms that change the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness.
All People in Business Stories